iOnctura's Chemo-Free Lung Cancer Combo Halves Severe Side Effects
Image
Geneva – November 06, 2026 -- iOnctura's chemo-free regimen of roginolisib plus dostarlimab produced grade 3 or higher treatment-emergent adverse events in 35% of patients with immunotherapy-resistant non-small cell lung cancer (NSCLC), against 75% in the chemotherapy-containing control arm, according to late-breaking Phase I/II PULMO-01 data presented at the SITC 2026 Annual Meeting.
The triplet arm, which added docetaxel to roginolisib and dostarlimab, recorded a 69% rate. No fatal adverse events were attributed to roginolisib.